ArriVent BioPharma, Inc. announced financial results for the full year ended December 31, 2025, reporting net loss of $166.3 million and cash and investments of $312.8 million expected to fund operations into 3Q 2027. The company highlighted progress on firmonertinib Phase 3 trials and ADC pipeline advancements.
Key takeaways
Cash and investments of $312.8 million as of December 31, 2025, expected to fund operations into 3Q 2027
Net loss of $166.3 million for year ended December 31, 2025 vs $80.5 million in 2024
Research and development expenses $153.4 million for 2025 vs $79.0 million in 2024
Topline Phase 3 data for firmonertinib in EGFR exon 20 insertion mutant NSCLC expected mid-2026
First patient dosed in Phase 3 ALPACCA study for EGFR PACC mutant NSCLC in December 2025
ARR-217 Phase 1 trial ongoing with first patient dosed in March 2026